236 related articles for article (PubMed ID: 31063799)
1. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Clémenson C; Liu W; Bricout D; Soyez-Herkert L; Chargari C; Mondini M; Haddad R; Wang-Zhang X; Benel L; Bloy C; Deutsch E
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1141-1152. PubMed ID: 31063799
[TBL] [Abstract][Full Text] [Related]
2. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Mangoni M; Yue X; Morin C; Violot D; Frascogna V; Tao Y; Opolon P; Castaing M; Auperin A; Biti G; Barritault D; Vozenin-Brotons MC; Deutsch E; Bourhis J
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1242-50. PubMed ID: 19545790
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl Sulfoxide Prevents Radiation-Induced Oral Mucositis Through Facilitating DNA Double-Strand Break Repair in Epithelial Stem Cells.
Yang C; Tang H; Wang L; Peng R; Bai F; Shan Y; Yu Z; Zhou P; Cong Y
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1577-1589. PubMed ID: 30092334
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
5. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Soref CM; Hacker TA; Fahl WE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e701-7. PubMed ID: 22330992
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.
Burdelya LG; Gleiberman AS; Toshkov I; Aygun-Sunar S; Bapardekar M; Manderscheid-Kern P; Bellnier D; Krivokrysenko VI; Feinstein E; Gudkov AV
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):228-34. PubMed ID: 22000579
[TBL] [Abstract][Full Text] [Related]
7. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
8. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Anné PR; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis.
Kouvaris J; Kouloulias V; Kokakis J; Matsopoulos G; Balafouta M; Miliadou A; Vlahos L
Onkologie; 2002 Aug; 25(4):364-9. PubMed ID: 12232489
[TBL] [Abstract][Full Text] [Related]
12. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
13. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
Trog D; Bank P; Wendt TG; Koscielny S; Beleites E
Strahlenther Onkol; 1999 Sep; 175(9):444-9. PubMed ID: 10518978
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
15. Amifostine--a radioprotector in locally advanced head and neck tumors.
Schönekäs KG; Wagner W; Prott FJ
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
[TBL] [Abstract][Full Text] [Related]
16. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
17. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.
Varghese JJ; Schmale IL; Mickelsen D; Hansen ME; Newlands SD; Benoit DSW; Korshunov VA; Ovitt CE
J Dent Res; 2018 Oct; 97(11):1252-1259. PubMed ID: 29634396
[TBL] [Abstract][Full Text] [Related]
18. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
19. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Hu K; Ship JA; Harrison LB
Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
[TBL] [Abstract][Full Text] [Related]
20. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
